Hongyan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hongyan Zhang has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Tingtao Chen
Jiangxi Province Key Laboratory of Bioengineering Drugs, School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, China
7 shared publications - Chunmao Han
Department of Burns & Wound Care Center, Second Affiliated Hospital of Zhejiang University, Hangzhou, China, China
3 shared publications Deqing Duan
Department of Burns, the First Affiliated Hospital of Nanchang University, Nanchang, China
3 shared publicationsJiamin Xu
Medical Center of Burn Plastic and Wound Repair , The First Affiliated Hospital; School of Basic Medical Sciences; Institute of Biomedical Innovation, Jiangxi Medical College Nanchang, Jiangxi 330031
3 shared publicationsJing Wei
National Engineering Research Center for Bioengineering Drugs and the Technologies Jiangxi
3 shared publications- Lixia Xiong
Department of Pathophysiology, Basic Medical College, Nanchang University, Nanchang 330006, China
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 15 (10)
Clostridium butyricum NCU-02 alleviates hyperlipidemia via activating hepatic PPARγ-LXRα-ABCA1 pathway and modulating the gut microbiota
Hyperlipidemia, characterized by aberrant lipid profiles, induces fatty deposits on arterial walls, thereby markedly increasing the risk of serious cardiovascular diseases like atherosclerosis. Probiotics have recently garnered attention as a promising strategy for managing hyperlipidemia since they offer lipid-lowering benefits for the host. In this study, we isolated Clostridium butyricum NCU-02 from centenarian fecal samples and evaluated its potential to mitigate hyperlipidemia in ApoE–/– mice fed a high-fat diet. We demonstrated that C. butyricum NCU-02 exhibited robust probiotic characteristics, including acid/bile tolerance, antibacterial activity, and enhanced growth capacity. Supplementation with C. butyricum NCU-02 significantly improved serum lipid levels, alleviated systemic inflammation, and mitigated oxidative stress. Moreover, C. butyricum NCU-02 activated the hepatic PPARγ-LXRα-ABCA1 pathway, facilitating cholesterol efflux and consequently reducing both hepatic injury markers and lipid accumulation. Furthermore, C. butyricum NCU-02 restored gut microbiota homeostasis in hyperlipidemic mice, characterized by alleviated the reduction in microbial diversity, improved intestinal barrier function, and modulated microbial composition. Notably, the increased Blautia, decreased Alistipes, and improved biochemical parameters were significantly correalted with anti-hyperlipidemic effects. These results highlight the therapeutic potential of C. butyricum NCU-02 as a probiotic intervention for hyperlipidemia, offering a multifaceted approach to lipid regulation and gut health modulation.
- 1 October 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 15 (10)
Open AccessClostridium butyricum NCU-02 alleviates hyperlipidemia via activating hepatic PPARγ-LXRα-ABCA1 pathway and modulating the gut microbiota
Hyperlipidemia, characterized by aberrant lipid profiles, induces fatty deposits on arterial walls, thereby markedly increasing the risk of serious cardiovascular diseases like atherosclerosis. Probiotics have recently garnered attention as a promising strategy for managing hyperlipidemia since they offer lipid-lowering benefits for the host. In this study, we isolated Clostridium butyricum NCU-02 from centenarian fecal samples and evaluated its potential to mitigate hyperlipidemia in ApoE–/– mice fed a high-fat diet. We demonstrated that C. butyricum NCU-02 exhibited robust probiotic characteristics, including acid/bile tolerance, antibacterial activity, and enhanced growth capacity. Supplementation with C. butyricum NCU-02 significantly improved serum lipid levels, alleviated systemic inflammation, and mitigated oxidative stress. Moreover, C. butyricum NCU-02 activated the hepatic PPARγ-LXRα-ABCA1 pathway, facilitating cholesterol efflux and consequently reducing both hepatic injury markers and lipid accumulation. Furthermore, C. butyricum NCU-02 restored gut microbiota homeostasis in hyperlipidemic mice, characterized by alleviated the reduction in microbial diversity, improved intestinal barrier function, and modulated microbial composition. Notably, the increased Blautia, decreased Alistipes, and improved biochemical parameters were significantly correalted with anti-hyperlipidemic effects. These results highlight the therapeutic potential of C. butyricum NCU-02 as a probiotic intervention for hyperlipidemia, offering a multifaceted approach to lipid regulation and gut health modulation.
- 19 June 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- p. 1-18
Effect of Engineered EcN-IFN-α2b on Human Papillomavirus Persistence in an NSG Surrogate Model
Currently, live biotherapeutic products (LBP) have been widely used to improve gut microbiota, enhance immunity, and promote digestion. Engineering bacteria, as one form of LBP, have made breakthrough progress in the treatment of diseases, but their effectiveness and specific mechanisms in treating vaginal infections are not clear. Here, we innovatively constructed Escherichia coli Nissle 1917-attB-IFN-α2b (EcN-IFN-α2b) expressing antiviral interferon alpha-2b (IFN-α2b) using genome integration technology, and evaluated its ability to reduce human papillomavirus (HPV) viral load and the underlying mechanisms in an NSG mouse surrogate model of HPV. Our results showed that EcN-IFN-α2b had good growth performance, acid resistance, antioxidant ability, and antimicrobial activity in vitro. EcN-IFN-α2b also significantly reduced the HPV viral load (M vs. EcN-IFN-α2b = 1.003 vs. 0.643, p < 0.01), and effectively alleviated the levels of interleukin 1β (IL-1β) (M vs. EcN-IFN-α2b, p < 0.01), interleukin 6 (IL-6) (M vs. EcN-IFN-α2b, p < 0.01), and tumor necrosis factor α (TNF-α) (M vs. EcN-IFN-α2b, p < 0.05) in the vagina. Further mechanistic studies suggested that EcN-IFN-α2b may reduce HPV viral load by activating the JAK/STAT/cGAS/STING signaling pathway. Additionally, we found that EcN-IFN-α2b altered the composition of vaginal microbiota, especially the relative abundance of vaginal pathogens such as Vibrionaceae_Vibrio, Streptococcus, and Staphylococcaceae_Staphylococcus, and the relative abundance of beneficial Lactobacillus. This study systematically evaluated the effects of the novel engineered strain EcN-IFN-α2b in reducing HPV viral load, alleviating associated inflammation, and restoring vaginal microbiota in an NSG mouse surrogate model, providing a new strategy for the future clinical treatment of HPV infection.
- 19 June 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- p. 1-18
Effect of Engineered EcN-IFN-α2b on Human Papillomavirus Persistence in an NSG Surrogate Model
Currently, live biotherapeutic products (LBP) have been widely used to improve gut microbiota, enhance immunity, and promote digestion. Engineering bacteria, as one form of LBP, have made breakthrough progress in the treatment of diseases, but their effectiveness and specific mechanisms in treating vaginal infections are not clear. Here, we innovatively constructed Escherichia coli Nissle 1917-attB-IFN-α2b (EcN-IFN-α2b) expressing antiviral interferon alpha-2b (IFN-α2b) using genome integration technology, and evaluated its ability to reduce human papillomavirus (HPV) viral load and the underlying mechanisms in an NSG mouse surrogate model of HPV. Our results showed that EcN-IFN-α2b had good growth performance, acid resistance, antioxidant ability, and antimicrobial activity in vitro. EcN-IFN-α2b also significantly reduced the HPV viral load (M vs. EcN-IFN-α2b = 1.003 vs. 0.643, p < 0.01), and effectively alleviated the levels of interleukin 1β (IL-1β) (M vs. EcN-IFN-α2b, p < 0.01), interleukin 6 (IL-6) (M vs. EcN-IFN-α2b, p < 0.01), and tumor necrosis factor α (TNF-α) (M vs. EcN-IFN-α2b, p < 0.05) in the vagina. Further mechanistic studies suggested that EcN-IFN-α2b may reduce HPV viral load by activating the JAK/STAT/cGAS/STING signaling pathway. Additionally, we found that EcN-IFN-α2b altered the composition of vaginal microbiota, especially the relative abundance of vaginal pathogens such as Vibrionaceae_Vibrio, Streptococcus, and Staphylococcaceae_Staphylococcus, and the relative abundance of beneficial Lactobacillus. This study systematically evaluated the effects of the novel engineered strain EcN-IFN-α2b in reducing HPV viral load, alleviating associated inflammation, and restoring vaginal microbiota in an NSG mouse surrogate model, providing a new strategy for the future clinical treatment of HPV infection.
- Open Access
- 25 August 2025
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 11 (1) , 1-17
Harnessing dual-channel probiotics to synergistically correct intestinal and vaginal dysbiosis after antibiotic disruption
Antibiotics are widely used to treat infectious diseases, yet antibiotic therapy has been shown to disrupt symbiotic microbiota. Notably, the dosage and duration of antibiotic use for specific infections may exert detrimental effects on microbiota in non-infected sites. Here, we propose a dual-channel probiotic delivery strategy to address gut and vaginal dysbiosis caused by antibiotic therapies. In a Helicobacter pylori infection model, oral administration of Limosilactobacillus reuteri NCU-15 alleviated gastritis and protected the intestinal barrier and microbiota. In a vaginal dysbiosis model, intravaginal delivery of Lactobacillus crispatus NCU-23 reduced local inflammation and apoptosis, restoring vaginal microbial homeostasis. In the entero-vaginal disordered mice, dual-channel probiotic therapy produced synergistic effects by reducing inflammation, inhibiting apoptosis, and reestablishing microbial balance. These findings demonstrate the potential of dual-channel probiotic intervention to modulate gut-vaginal microbiota interactions and offer a scientific basis for developing strategies to prevent or treat antibiotic-induced dysbiosis.
- 25 August 2025
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 11 (1) , 1-17
Open AccessHarnessing dual-channel probiotics to synergistically correct intestinal and vaginal dysbiosis after antibiotic disruption
Antibiotics are widely used to treat infectious diseases, yet antibiotic therapy has been shown to disrupt symbiotic microbiota. Notably, the dosage and duration of antibiotic use for specific infections may exert detrimental effects on microbiota in non-infected sites. Here, we propose a dual-channel probiotic delivery strategy to address gut and vaginal dysbiosis caused by antibiotic therapies. In a Helicobacter pylori infection model, oral administration of Limosilactobacillus reuteri NCU-15 alleviated gastritis and protected the intestinal barrier and microbiota. In a vaginal dysbiosis model, intravaginal delivery of Lactobacillus crispatus NCU-23 reduced local inflammation and apoptosis, restoring vaginal microbial homeostasis. In the entero-vaginal disordered mice, dual-channel probiotic therapy produced synergistic effects by reducing inflammation, inhibiting apoptosis, and reestablishing microbial balance. These findings demonstrate the potential of dual-channel probiotic intervention to modulate gut-vaginal microbiota interactions and offer a scientific basis for developing strategies to prevent or treat antibiotic-induced dysbiosis.
- Open Access
- 29 January 2025
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2025 (1) , 6675676
Administration of a Next‐Generation Probiotic Escherichia coli Nissle 1917‐GLP‐1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes
Diabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first‐line therapies in selected instances, as per the updated ADA guidelines, highlighting their efficacy not only in glycemic control but also in their broader health benefits. Nonetheless, the efficacy of GLP‐1 is limited by its brief duration of action, rapid clearance from the body, and challenges associated with subcutaneous administration. In this study, we examined the potential diabetes‐mitigating effects of a genetically engineered strain of Escherichia coli Nissle 1917 (EcN)‐GLP‐1, previously developed by our group. We utilized mouse models for both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) to assess its efficacy. In the case of T1DM mice, the results revealed that EcN‐GLP‐1 resulted in a notable decrease in blood glucose levels. Furthermore, it exhibited a protective influence on the structural integrity of islet β ‐cells; downregulated the expressions of key inflammatory markers such as TLR‐4, p‐NF‐ κ B/NF‐ κ B, and Bax/Bcl‐2; promoted the insulin secretion; and reinstated the perturbed diversity of microbial species to a normal state. Similarly, EcN‐GLP‐1 had a pronounced impact on T2DM mice, manifesting increased presence of islet β ‐cells, decreased inflammatory response and apoptosis, and regulation of lipid metabolism in the liver. In summary, the genetically modified EcN‐GLP‐1 strain demonstrates the ability to alleviate diabetes by enhancing the islet β ‐cell population, mitigating inflammatory reactions and apoptosis, optimizing liver lipid metabolism, and reinstating a balanced microbial diversity. These findings hold promise as a potential avenue for treating DM.
- 29 January 2025
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2025 (1) , 6675676
Open AccessAdministration of a Next‐Generation Probiotic Escherichia coli Nissle 1917‐GLP‐1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes
Diabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first‐line therapies in selected instances, as per the updated ADA guidelines, highlighting their efficacy not only in glycemic control but also in their broader health benefits. Nonetheless, the efficacy of GLP‐1 is limited by its brief duration of action, rapid clearance from the body, and challenges associated with subcutaneous administration. In this study, we examined the potential diabetes‐mitigating effects of a genetically engineered strain of Escherichia coli Nissle 1917 (EcN)‐GLP‐1, previously developed by our group. We utilized mouse models for both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) to assess its efficacy. In the case of T1DM mice, the results revealed that EcN‐GLP‐1 resulted in a notable decrease in blood glucose levels. Furthermore, it exhibited a protective influence on the structural integrity of islet β ‐cells; downregulated the expressions of key inflammatory markers such as TLR‐4, p‐NF‐ κ B/NF‐ κ B, and Bax/Bcl‐2; promoted the insulin secretion; and reinstated the perturbed diversity of microbial species to a normal state. Similarly, EcN‐GLP‐1 had a pronounced impact on T2DM mice, manifesting increased presence of islet β ‐cells, decreased inflammatory response and apoptosis, and regulation of lipid metabolism in the liver. In summary, the genetically modified EcN‐GLP‐1 strain demonstrates the ability to alleviate diabetes by enhancing the islet β ‐cell population, mitigating inflammatory reactions and apoptosis, optimizing liver lipid metabolism, and reinstating a balanced microbial diversity. These findings hold promise as a potential avenue for treating DM.
- 2 January 2025
- Published by Oxford University Press (OUP) in Burns & Trauma
- Vol. 13, tkaf002
Research progress on the role of fascia in skin wound healing
The skin, the human body’s largest organ, is perpetually exposed to environmental factors, rendering it vulnerable to potential injuries. Fascia, a vital connective tissue that is extensively distributed throughout the body, fulfils multiple functions, including support, compartmentalization, and force transmission. The role of fascia in skin wound healing has recently attracted considerable attention. In addition to providing mechanical support, fascia significantly contributes to intercellular signalling and tissue repair, establishing itself as a crucial participant in wound healing. This review synthesises the latest advancements in fascia research and its implications for skin wound healing.
- 2 January 2025
- Published by Oxford University Press (OUP) in Burns & Trauma
- Vol. 13, tkaf002
Research progress on the role of fascia in skin wound healing
The skin, the human body’s largest organ, is perpetually exposed to environmental factors, rendering it vulnerable to potential injuries. Fascia, a vital connective tissue that is extensively distributed throughout the body, fulfils multiple functions, including support, compartmentalization, and force transmission. The role of fascia in skin wound healing has recently attracted considerable attention. In addition to providing mechanical support, fascia significantly contributes to intercellular signalling and tissue repair, establishing itself as a crucial participant in wound healing. This review synthesises the latest advancements in fascia research and its implications for skin wound healing.
- 18 December 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (2) , 475-486
Lactobacillus rhamnosus LC-STH-13 ameliorates the progression of SLE in MRL/lpr mice by inhibiting the TLR9/NF-κB signaling pathway
Lactobacillus rhamnosus LC-STH-13 ameliorates the progression of SLE in MRL/lpr mice by modulating the gut microbiota and inhibiting the TLR9/NF-κB signaling pathway.
- 18 December 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (2) , 475-486
Lactobacillus rhamnosus LC-STH-13 ameliorates the progression of SLE in MRL/lpr mice by inhibiting the TLR9/NF-κB signaling pathway
Lactobacillus rhamnosus LC-STH-13 ameliorates the progression of SLE in MRL/lpr mice by modulating the gut microbiota and inhibiting the TLR9/NF-κB signaling pathway.
- Open Access
- 4 October 2024
- Published by Elsevier in Current Research in Food Science
- Vol. 9, 100875
Lacticaseibacillus paracasei NCU-04 relieves constipation and the depressive-like behaviors induced by loperamide in mice through the microbiome-gut-brain axis
- 4 October 2024
- Published by Elsevier in Current Research in Food Science
- Vol. 9, 100875
Open AccessLacticaseibacillus paracasei NCU-04 relieves constipation and the depressive-like behaviors induced by loperamide in mice through the microbiome-gut-brain axis
- Open Access
Effectiveness of Psychobiotic Bifidobacterium breve BB05 in Managing Psychosomatic Diarrhea in College Students by Regulating Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial
Diarrhea of college students (DCS) is a prevalent issue among college students, affecting their daily lives and academic performance. This study aims to explore the potential effect of Bifidobacterium breve BB05 supplements on the DCS. Initially, fifty healthy and fifty diarrheal students were recruited in the observational experiment and allocated into control and diarrhea groups, respectively. Subsequently, one hundred diarrheal students were newly recruited in the intervention experiment and randomly allocated into placebo and probiotic groups, both treated for 2 weeks. Questionnaires (BSS, HAMA-14, and HDRS-17) were performed to assess the students’ diarrheal states and mental health at baseline and post-treatment. Fecal samples underwent 16S rRNA sequencing and Enzyme-Linked Immunosorbent Assay to evaluate gut microbiota and fecal metabolite alternations. Results indicated that B. breve BB05 supplementation significantly enriched (p < 0.05) the reduced gut microbial diversity caused by diarrhea. Diarrhea resulted in notable alterations in gut microbiota composition, as exhibited by elevated Collinsella and Streptococcus, alongside substantially decreased Bifidobacterium, Bacteroides, and Prevotella, while B. breve BB05 supplementation partially restored the compromised gut microbiota at both the phylum and genus levels, particularly by increasing Bifidobacterium and Roseburia (p < 0.05). Importantly, questionnaire results suggested that B. breve BB05 administration achieved superior efficacy in relieving diarrhea symptoms and the associated anxiety and depression in college students. An increased fecal concentration of 5-hydroxytryptamine (5-HT) was also observed in the probiotic group, while Acetylcholine (ACH), Epinephrine (EPI), and Noradrenaline/Norepinephrine (NANE) reduced, revealing the potential of B. breve BB05 in alleviating anxiety and depression via modulating the microbiota–gut–brain axis. Furthermore, correlation analysis suggested that the altered microbiota and fecal neurotransmitters were closely associated with the mental symptoms. These results endorse B. breve BB05 intervention as a promising and innovative approach to alleviate both diarrhea and mental health conditions among college students.
Open AccessEffectiveness of Psychobiotic Bifidobacterium breve BB05 in Managing Psychosomatic Diarrhea in College Students by Regulating Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial
Diarrhea of college students (DCS) is a prevalent issue among college students, affecting their daily lives and academic performance. This study aims to explore the potential effect of Bifidobacterium breve BB05 supplements on the DCS. Initially, fifty healthy and fifty diarrheal students were recruited in the observational experiment and allocated into control and diarrhea groups, respectively. Subsequently, one hundred diarrheal students were newly recruited in the intervention experiment and randomly allocated into placebo and probiotic groups, both treated for 2 weeks. Questionnaires (BSS, HAMA-14, and HDRS-17) were performed to assess the students’ diarrheal states and mental health at baseline and post-treatment. Fecal samples underwent 16S rRNA sequencing and Enzyme-Linked Immunosorbent Assay to evaluate gut microbiota and fecal metabolite alternations. Results indicated that B. breve BB05 supplementation significantly enriched (p < 0.05) the reduced gut microbial diversity caused by diarrhea. Diarrhea resulted in notable alterations in gut microbiota composition, as exhibited by elevated Collinsella and Streptococcus, alongside substantially decreased Bifidobacterium, Bacteroides, and Prevotella, while B. breve BB05 supplementation partially restored the compromised gut microbiota at both the phylum and genus levels, particularly by increasing Bifidobacterium and Roseburia (p < 0.05). Importantly, questionnaire results suggested that B. breve BB05 administration achieved superior efficacy in relieving diarrhea symptoms and the associated anxiety and depression in college students. An increased fecal concentration of 5-hydroxytryptamine (5-HT) was also observed in the probiotic group, while Acetylcholine (ACH), Epinephrine (EPI), and Noradrenaline/Norepinephrine (NANE) reduced, revealing the potential of B. breve BB05 in alleviating anxiety and depression via modulating the microbiota–gut–brain axis. Furthermore, correlation analysis suggested that the altered microbiota and fecal neurotransmitters were closely associated with the mental symptoms. These results endorse B. breve BB05 intervention as a promising and innovative approach to alleviate both diarrhea and mental health conditions among college students.
- Open Access
- 9 March 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-15
Transcriptome and single-cell transcriptomics reveal prognostic value and potential mechanism of anoikis in skin cutaneous melanoma
Background Skin cutaneous melanoma (SKCM) is a highly lethal cancer, ranking among the top four deadliest cancers. This underscores the urgent need for novel biomarkers for SKCM diagnosis and prognosis. Anoikis plays a vital role in cancer growth and metastasis, and this study aims to investigate its prognostic value and mechanism of action in SKCM. Methods Utilizing consensus clustering, the SKCM samples were categorized into two distinct clusters A and B based on anoikis-related genes (ANRGs), with the B group exhibiting lower disease-specific survival (DSS). Gene set enrichment between distinct clusters was examined using Gene Set Variation Analysis (GSVA) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Results We created a predictive model based on three anoikis-related differently expressed genes (DEGs), specifically, FASLG, IGF1, and PIK3R2. Moreover, the mechanism of these prognostic genes within the model was investigated at the cellular level using the single-cell sequencing dataset GSE115978. This analysis revealed that the FASLG gene was highly expressed on cluster 1 of Exhausted CD8( +) T (Tex) cells. Conclusions In conclusion, we have established a novel classification system for SKCM based on anoikis, which carries substantial clinical implications for SKCM patients. Notably, the elevated expression of the FASLG gene on cluster 1 of Tex cells could significantly impact SKCM prognosis through anoikis, thus offering a promising target for the development of immunotherapy for SKCM.
- 9 March 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-15
Open AccessTranscriptome and single-cell transcriptomics reveal prognostic value and potential mechanism of anoikis in skin cutaneous melanoma
Background Skin cutaneous melanoma (SKCM) is a highly lethal cancer, ranking among the top four deadliest cancers. This underscores the urgent need for novel biomarkers for SKCM diagnosis and prognosis. Anoikis plays a vital role in cancer growth and metastasis, and this study aims to investigate its prognostic value and mechanism of action in SKCM. Methods Utilizing consensus clustering, the SKCM samples were categorized into two distinct clusters A and B based on anoikis-related genes (ANRGs), with the B group exhibiting lower disease-specific survival (DSS). Gene set enrichment between distinct clusters was examined using Gene Set Variation Analysis (GSVA) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Results We created a predictive model based on three anoikis-related differently expressed genes (DEGs), specifically, FASLG, IGF1, and PIK3R2. Moreover, the mechanism of these prognostic genes within the model was investigated at the cellular level using the single-cell sequencing dataset GSE115978. This analysis revealed that the FASLG gene was highly expressed on cluster 1 of Exhausted CD8( +) T (Tex) cells. Conclusions In conclusion, we have established a novel classification system for SKCM based on anoikis, which carries substantial clinical implications for SKCM patients. Notably, the elevated expression of the FASLG gene on cluster 1 of Tex cells could significantly impact SKCM prognosis through anoikis, thus offering a promising target for the development of immunotherapy for SKCM.
- Open Access
- 5 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Causal relationship between telomere length and sepsis: a bidirectional Mendelian randomization study
Numerous observational studies have elucidated a connection between leukocyte telomere length (LTL) and sepsis, yet its fundamental cause remains enigmatic. Thus, the current study’s objective is to employ a bidirectional Mendelian randomization (MR) approach to scrutinize the causality between LTL and sepsis. We selected single nucleotide polymorphisms (SNPs) associated with LTL (n = 472,174) and sepsis from a genome-wide association study (GWAS), including Sepsis (n = 486,484, ncase = 11,643), Sepsis (28 day death in critical care) (n = 431,365, ncase = 347), Sepsis (under 75) (n = 462,869, ncase = 11,568), Sepsis (28 day death) (n = 486,484, ncase = 1896), and Sepsis (critical care) (n = 431,365, ncase = 1380), as instrumental variables (IVs). The inverse variance weighted (IVW) MR method was employed as the primary approach, and various sensitivity analyses were conducted to assess the validity of this instrument and potential pleiotropy. Using the IVW method, we uncovered a potential causal relationship between genetically predicted LTL reduction and increased susceptibility to sepsis, with an odds ratio (OR) of 1.161 [95% confidence interval (CI) 1.039–1.297, p = 0.008]. However, reverse MR analysis did not indicate any impact of sepsis on LTL. Our forward MR study highlights a potential causal relationship between LTL as an exposure and increased susceptibility to sepsis. Specifically, our findings suggest that individuals with genetically determined shorter LTL may be at an increased risk of developing sepsis. This may contribute to the development of novel diagnostic and therapeutic strategies for the prevention, diagnosis, and treatment of sepsis.
- 5 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessCausal relationship between telomere length and sepsis: a bidirectional Mendelian randomization study
Numerous observational studies have elucidated a connection between leukocyte telomere length (LTL) and sepsis, yet its fundamental cause remains enigmatic. Thus, the current study’s objective is to employ a bidirectional Mendelian randomization (MR) approach to scrutinize the causality between LTL and sepsis. We selected single nucleotide polymorphisms (SNPs) associated with LTL (n = 472,174) and sepsis from a genome-wide association study (GWAS), including Sepsis (n = 486,484, ncase = 11,643), Sepsis (28 day death in critical care) (n = 431,365, ncase = 347), Sepsis (under 75) (n = 462,869, ncase = 11,568), Sepsis (28 day death) (n = 486,484, ncase = 1896), and Sepsis (critical care) (n = 431,365, ncase = 1380), as instrumental variables (IVs). The inverse variance weighted (IVW) MR method was employed as the primary approach, and various sensitivity analyses were conducted to assess the validity of this instrument and potential pleiotropy. Using the IVW method, we uncovered a potential causal relationship between genetically predicted LTL reduction and increased susceptibility to sepsis, with an odds ratio (OR) of 1.161 [95% confidence interval (CI) 1.039–1.297, p = 0.008]. However, reverse MR analysis did not indicate any impact of sepsis on LTL. Our forward MR study highlights a potential causal relationship between LTL as an exposure and increased susceptibility to sepsis. Specifically, our findings suggest that individuals with genetically determined shorter LTL may be at an increased risk of developing sepsis. This may contribute to the development of novel diagnostic and therapeutic strategies for the prevention, diagnosis, and treatment of sepsis.